Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00506077 | MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) | PHASE2 | COMPLETED | 55 | — | — | Dec 1, 2007 | Oct 1, 2008 | Aug 3, 2015 | - | — |
The mean change from baseline after 4 weeks of treatment in total cognitive score on the BACS was calculated as a weighted average of T-scores (normalized for age) from BACS subtests including Verbal Memory, Digit Sequencing, Token Motor, Symbol Coding, Semantic Fluency, Letter Fluency, and Tower of London. The minimum and maximum values possible for this composite T-score of the change from baseline were -131 and 131, respectively. Higher values (positive changes from baseline) indicate better performance.
| Arm | Type | Description |
|---|---|---|
| MK0249 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MK0249 | DRUG | MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days. |
| Comparator: Placebo (unspecified) | DRUG | MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period. |
Inclusion Criteria: * Patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months * Patient has a 6th grade reading level or better * Females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth...